{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "priceEpsCurrentYear": -4.087591, "sharesOutstanding": 184643008, "bookValue": 2.238, "fiftyDayAverage": 6.3178, "fiftyDayAverageChange": -0.71780014, "fiftyDayAverageChangePercent": -0.11361552, "twoHundredDayAverage": 8.84525, "twoHundredDayAverageChange": -3.2452502, "twoHundredDayAverageChangePercent": -0.36689186, "marketCap": 1122010368, "forwardPE": -3.5668788, "priceToBook": 2.5022342, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-04-16", "averageAnalystRating": "2.6 - Hold", "tradeable": false, "cryptoTradeable": false, "exchange": "NMS", "shortName": "Recursion Pharmaceuticals, Inc.", "longName": "Recursion Pharmaceuticals, Inc.", "messageBoardId": "finmb_261401243", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "regularMarketChangePercent": 5.860112, "regularMarketPrice": 5.6, "firstTradeDateMilliseconds": 1618579800000, "priceHint": 2, "regularMarketChange": 0.30999994, "regularMarketTime": 1684180805, "regularMarketDayHigh": 5.715, "regularMarketDayRange": "5.19 - 5.715", "regularMarketDayLow": 5.19, "regularMarketVolume": 1318863, "regularMarketPreviousClose": 5.29, "bid": 0.0, "ask": 0.0, "bidSize": 12, "askSize": 8, "fullExchangeName": "NasdaqGS", "financialCurrency": "USD", "regularMarketOpen": 5.31, "averageDailyVolume3Month": 1193821, "averageDailyVolume10Day": 1679420, "fiftyTwoWeekLowChange": 1.06, "fiftyTwoWeekLowChangePercent": 0.23348017, "fiftyTwoWeekRange": "4.54 - 14.18", "fiftyTwoWeekHighChange": -8.58, "fiftyTwoWeekHighChangePercent": -0.60507756, "fiftyTwoWeekLow": 4.54, "fiftyTwoWeekHigh": 14.18, "earningsTimestamp": 1683548079, "earningsTimestampStart": 1691405940, "earningsTimestampEnd": 1691755200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.25, "epsForward": -1.57, "epsCurrentYear": -1.37, "displayName": "Recursion Pharmaceuticals", "symbol": "RXRX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "41 South Rio Grande Street", "city": "Salt Lake City", "state": "UT", "zip": "84101", "country": "United States", "phone": "385 269 0203", "fax": "801 821 2872", "website": "https://www.recursion.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.", "fullTimeEmployees": 500, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher C. Gibson Ph.D.", "age": 39, "title": "Co-Founder, CEO & Director", "yearBorn": 1983, "fiscalYear": 2022, "totalPay": {"raw": 695178, "fmt": "695.18k", "longFmt": "695,178"}, "exercisedValue": {"raw": 2794936, "fmt": "2.79M", "longFmt": "2,794,936"}, "unexercisedValue": {"raw": 163438, "fmt": "163.44k", "longFmt": "163,438"}}, {"maxAge": 1, "name": "Ms. Tina Marriott Larson", "age": 47, "title": "COO & Pres", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": {"raw": 612689, "fmt": "612.69k", "longFmt": "612,689"}, "exercisedValue": {"raw": 757472, "fmt": "757.47k", "longFmt": "757,472"}, "unexercisedValue": {"raw": 4404300, "fmt": "4.4M", "longFmt": "4,404,300"}}, {"maxAge": 1, "name": "Dr. Blake C. Borgeson Ph.D.", "age": 40, "title": "Co-Founder & Director", "yearBorn": 1982, "fiscalYear": 2022, "totalPay": {"raw": 39999, "fmt": "40k", "longFmt": "39,999"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Michael  Secora Ph.D.", "age": 39, "title": "Chief Financial Officer", "yearBorn": 1983, "fiscalYear": 2022, "totalPay": {"raw": 524188, "fmt": "524.19k", "longFmt": "524,188"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 6742406, "fmt": "6.74M", "longFmt": "6,742,406"}}, {"maxAge": 1, "name": "Dr. Shafique  Virani M.D.", "age": 51, "title": "Interim Chief Medical Officer & Chief Corp. Devel. Officer", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 681839, "fmt": "681.84k", "longFmt": "681,839"}, "exercisedValue": {"raw": 259458, "fmt": "259.46k", "longFmt": "259,458"}, "unexercisedValue": {"raw": 1455289, "fmt": "1.46M", "longFmt": "1,455,289"}}, {"maxAge": 1, "name": "Kevin  Leggat", "title": "VP of Fin. & Accounting", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Benjamin  Mabey M.S.", "age": 39, "title": "Chief Technology Officer", "yearBorn": 1983, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jared  Allenbach", "title": "Sr. Director of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ryan  Kelly", "title": "Chief Communications Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Heather  Kirkby M.B.A.", "age": 49, "title": "Chief People Officer", "yearBorn": 1973, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 1, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}